Agree. I'm back on board with this one. Money in the bank, plenty of news flow coming up. What sort of data are we expecting from the STEP trial? Is it just safety data, or efficacy too? Does anyone know whether the STEP trial can be used to get conditional approval in Japan by demonstrating "predicted efficacy", or do we need phase 2 data for that?
Director buying on open market is good to see, although this was not a significant investment in the scheme of things. This space has been a little quiet for some time and RGS has been flying under the radar. Some decent volume could push this upwards pretty quickly which is a positive.
RGS Price at posting:
13.5¢ Sentiment: Sell Disclosure: Not Held
